Los Angeles Capital Management LLC Has $1.30 Million Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Los Angeles Capital Management LLC lowered its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 14.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 276,881 shares of the biopharmaceutical company’s stock after selling 48,080 shares during the period. Los Angeles Capital Management LLC owned 0.48% of Vanda Pharmaceuticals worth $1,299,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its holdings in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares during the period. ORG Wealth Partners LLC acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $40,000. SG Americas Securities LLC lifted its stake in shares of Vanda Pharmaceuticals by 88.5% in the 3rd quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 9,580 shares during the period. Nantahala Capital Management LLC boosted its position in shares of Vanda Pharmaceuticals by 57.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock valued at $9,003,000 after purchasing an additional 580,265 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC grew its stake in Vanda Pharmaceuticals by 2.1% during the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock worth $1,625,000 after purchasing an additional 5,994 shares during the period. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Stock Down 6.6 %

NASDAQ VNDA opened at $5.10 on Friday. Vanda Pharmaceuticals Inc. has a 52 week low of $3.32 and a 52 week high of $6.75. The business has a 50 day moving average price of $4.80 and a 200-day moving average price of $5.26. The company has a market cap of $297.38 million, a price-to-earnings ratio of -18.21 and a beta of 0.77.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. StockNews.com assumed coverage on Vanda Pharmaceuticals in a report on Saturday, November 9th. They set a “hold” rating on the stock. Cantor Fitzgerald increased their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Finally, HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, October 31st. They issued a “buy” rating and a $18.00 price target for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.